facebook pixel Phone 212 693 530* *Fixed network call charges according to your tariff Search for your nearest Collection Point

212 693 530*

Collection Points

Phone 212 693 530* *Fixed network call charges according to your tariff

Monkeypox

Published: May 19, 2022

Current Situation in PORTUGAL, June 2023

The latest statistical data available in Portugal dates back to November 2022, when 948 cases were reported in connection with the Monkeypox virus (MPV) outbreak in the Lisbon and Tagus Valley region.
Portugal was one of the first countries to detect cases of infection. Starting in July 2022, a vaccine was made available and recommended for at-risk groups.
Although the circulation of the virus is currently considered low, this does not mean it has been eradicated, so surveillance will continue. Summer recreational activities may be linked to its resurgence, and vaccination is recommended for people at risk.

Virus

The Monkeypox virus belongs to the genus Orthopoxvirus of the family Poxviridae. It is a double-stranded DNA virus.

Epidemiological History of the Virus in the U.S. and Europe

The monkeypox virus is endemic to Central Africa and was first described in Denmark in 1958; the first case of human infection with monkeypox occurred in 1970 in the Democratic Republic of the Congo. In 2003, there was an outbreak in the U.S. with 47 confirmed cases and no deaths. In 2018, two confirmed cases were detected in the United Kingdom, both believed to have originated in Nigeria; one of these cases led to the first human-to-human transmission in Europe. In 2019, there was another confirmed case in the United Kingdom.

Signs and Symptoms

MPV infection is similar to smallpox, with the exception that MPV may cause lymphadenopathy. The incubation period is typically 7 to 14 days, though it can range from 5 to 21 days. Symptoms initially include fever, headaches, muscle and lower back pain, chills, and fatigue, followed by macules, papules, vesicles, pustules, and scabs. The disease is mostly self-limiting and lasts approximately 2 to 4 weeks.

Transmission

Primary transmission occurs from animals to humans, but secondary transmission can also occur from human to human. Transmission occurs through mucous membranes (eyes, mouth, nose), the respiratory tract, and broken skin (even if the wound is not visible to the naked eye), as well as through contact with contaminated bodily fluids or contaminated clothing or fabrics.

 Prevention

Avoid physical contact with people exhibiting the aforementioned symptoms for the entire duration of these signs and symptoms. Sharing clothing, towels, or sheets is also discouraged.

Since July 2022, a third-generation smallpox vaccine has been available, which is also effective against MPV. Currently, the following groups are eligible for vaccination:

  1. Groups at increased risk of human infection with MPV, in the context of preventive vaccination
  2. People who have had close contact with a confirmed case of infection—that is, in the context of post-exposure vaccination against the virus.

Treatment

Most cases require only supportive care, such as drinking plenty of fluids to stay hydrated and, if necessary, taking medications to relieve symptoms like pain and fever. In more severe cases, hospitalization may be necessary.

Diagnosis

Clinical suspicion can be confirmed by collecting exudate from the scab and biological fluid from the vesicles for amplification via Polymerase Chain Reaction (PCR) and testing for the gene that produces a fusion protein present in all Orthopoxviruses, including MPV, followed by confirmation in positive samples that the virus is indeed MPV. This sample collection should be performed by qualified professionals using personal protective equipment, including gloves, an FFP3 respirator, protective eyewear, and a lab coat.


See DGS Statement

If you have any questions, please contact us.
We'll be happy to help.

CLINICAL PATHOLOGY LABORATORY

CLINICAL PATHOLOGY LABORATORY
EMAIL

Phone 212 693 530*

*Fixed network call charges according to your tariff